The discovery of S-IIPhas sparked the resurgence of K-Ras drug discovery, leading to twoUS FDA-approved drugs, sotorasib and adagrasib, to treat K-Ras­(G12C)mutation driven non-small-cell lung cancer., However,there are no approved drugs targeting the most common K-Ras mutation,G12D. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.